Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compassionate Use of Esuberaprost for PAH
NCT01966302Phase 2Completed
- Sponsor
- The Lundquist Institute
- Start
- Nov 2013
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of esuberaprost in pulmonary arterial hypertension (PAH), sponsored by The Lundquist Institute. Started Nov 2013; status: completed.
02
Drugs
esuberaprost
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01966302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01966302.